Philogen S.p.a.

Philochem Ag

Manuela Kaspar

Eveline Trachsel

Dario Neri

Kathrin Schwager

Christoph Schliemann

The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.

Antigen associated with rheumatoid arthritis

Antibodies which bind an antigen of the bone marrow neovasculature in leukemia patients, for use in treatment and diagnosis of leukemia, in particular the treatment and diagnosis of acute myeloid leukemia (AML).

Targeting of bone marrow neovasculature

Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).

The present invention relates to fusion proteins comprising an antibody, functional fragment or functional derivative thereof having specific binding affinity to either the extracellular domain of oncofetal fibronectin (ED-B) or at least one of the extracellular domains of oncofetal tenascin fused to a cytokine selected from the group consisting of IL-10, IL15, IL-24 and GM-CSF, functional fragments and functional derivatives thereof. The invention is also directed to the use of at least one of said fusion proteins for the manufacture of a medicament. In particular, the invention concerns the use of said medicament for the treatment of tumors or chronic inflammatory diseases such as atherosclerosis, arthritis and psoriasis.

Growing community of inventors

Brugg, Switzerland

Manuela Kaspar